BiotechTube
Ten Boron

Ten Boron

Turku, Finland· Est.
tenboron.fi
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Tenboron is a Finnish biotech pioneering next-generation carriers for Boron Neutron Capture Therapy (BNCT), a targeted radiotherapy. The company is advancing a clinical-stage pipeline led by TB0010, an antibody-boron conjugate for recurrent head and neck cancer, with Phase 1b trials on the horizon. Founded in 2010, it leverages a seasoned leadership team with deep experience in oncology drug development and BNCT. Tenboron operates as a private, pre-revenue entity, relying on partnerships for manufacturing and clinical research.

Oncology

Technology Platform

Proprietary design and development of novel boron-10 carriers for Boron Neutron Capture Therapy (BNCT). The platform focuses on creating conjugates with high boron payload, selective tumor targeting (e.g., via antibodies), efficient cellular internalization, and optimized pharmacokinetics to maximize the tumor-to-healthy tissue concentration ratio.

Opportunities

The global expansion of hospital-based, accelerator-driven neutron sources creates a growing, addressable market for approved boron carriers.
Success in recurrent head and neck cancer, a high-unmet-need area, can serve as a clinical proof-of-concept to expand into other solid tumor indications like glioblastoma or melanoma, leveraging the same platform technology.

Risk Factors

Clinical failure of the lead candidate TB0010 remains a primary risk, as the novel carrier's performance in humans is unproven.
Commercial success is heavily dependent on the widespread clinical adoption and reimbursement of BNCT technology itself, which faces competition from other advanced radiotherapies.
As a pre-revenue private company, securing sufficient funding to complete clinical development is an ongoing challenge.

Competitive Landscape

Tenboron competes in the niche BNCT carrier space with other biotechs and academic institutions globally. Traditional agents (BPA, BSH) are generic and suboptimal. Competition includes companies like Stella Pharma (Japan) with its BPA formulation and others developing novel boron compounds. The broader competitive field includes all targeted radiotherapies (e.g., Lutathera, Pluvicto) and advanced external beam radiation technologies.

More companies in Radiopharmaceuticals →More companies in Finland →